Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers.

Stevens MW, Henry RL, Owens SM, Schutz R, Gentry WB.

MAbs. 2014;6(6):1649-56. doi: 10.4161/19420862.2014.976431.

2.

Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development.

Laurenzana EM, Stevens MW, Frank JC, Hambuchen MD, Hendrickson HP, White SJ, Williams DK, Owens SM, Gentry WB.

Hum Vaccin Immunother. 2014;10(9):2638-47. doi: 10.4161/hv.29707. Epub 2014 Nov 1.

3.

Treatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy.

White SJ, Hendrickson HP, Atchley WT, Laurenzana EM, Gentry WB, Williams DK, Owens SM.

Drug Metab Dispos. 2014 Aug;42(8):1285-91. doi: 10.1124/dmd.114.056879. Epub 2014 May 19.

4.

Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use.

Stevens MW, Tawney RL, West CM, Kight AD, Henry RL, Owens SM, Gentry WB.

MAbs. 2014 Mar-Apr;6(2):547-55. doi: 10.4161/mabs.27620. Epub 2013 Dec 23.

5.

Customizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applications.

Peterson EC, Gentry WB, Owens SM.

Adv Pharmacol. 2014;69:107-27. doi: 10.1016/B978-0-12-420118-7.00003-2. Review.

6.

Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure.

Sanders NC, Mancino MJ, Gentry WB, Guise JB, Bickel WK, Thostenson J, Oliveto AH.

Exp Clin Psychopharmacol. 2013 Aug;21(4):294-302. doi: 10.1037/a0033724. Epub 2013 Jul 15.

7.

Ketamine infusion as a treatment for major depressive disorder: a new role for anesthesiologists?

Dilley JD, Gentry WB, Golden KJ.

Middle East J Anaesthesiol. 2012 Oct;21(6):871-3. No abstract available.

PMID:
23634571
8.

Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction.

Owens SM, Atchley WT, Hambuchen MD, Peterson EC, Gentry WB.

CNS Neurol Disord Drug Targets. 2011 Dec;10(8):892-8. Review.

9.

Chronic anti-phencyclidine monoclonal antibody therapy decreases phencyclidine-induced in utero fetal mortality in pregnant rats.

Hubbard JJ, Laurenzana EM, Williams DK, Gentry WB, Owens SM.

Int Immunopharmacol. 2011 Dec;11(12):2181-7. doi: 10.1016/j.intimp.2011.09.016. Epub 2011 Oct 12.

10.

Gestation time-dependent pharmacokinetics of intravenous (+)-methamphetamine in rats.

White S, Laurenzana E, Hendrickson H, Gentry WB, Owens SM.

Drug Metab Dispos. 2011 Sep;39(9):1718-26. doi: 10.1124/dmd.111.039446. Epub 2011 Jun 1.

11.

The fate and function of therapeutic antiaddiction monoclonal antibodies across the reproductive cycle of rats.

Hubbard JJ, Laurenzana EM, Williams DK, Gentry WB, Owens SM.

J Pharmacol Exp Ther. 2011 Feb;336(2):414-22. doi: 10.1124/jpet.110.175083. Epub 2010 Oct 20.

12.

Anti-(+)-methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addiction.

Gentry WB, Rüedi-Bettschen D, Owens SM.

Clin Pharmacol Ther. 2010 Sep;88(3):390-3. doi: 10.1038/clpt.2010.155. Epub 2010 Jul 28.

13.

Behavioral effects of gamma-hydroxybutyrate in humans.

Oliveto A, Gentry WB, Pruzinsky R, Gonsai K, Kosten TR, Martell B, Poling J.

Behav Pharmacol. 2010 Jul;21(4):332-42. doi: 10.1097/FBP.0b013e32833b3397.

14.

Preparedness and disaster response training for veterinary students: literature review and description of the North Carolina State University Credentialed Veterinary Responder Program.

Dunning D, Martin MP, Tickel JL, Gentry WB, Cowen P, Slenning BD.

J Vet Med Educ. 2009 Fall;36(3):317-30. doi: 10.3138/jvme/013. Review.

PMID:
19861720
15.

Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats.

Laurenzana EM, Hendrickson HP, Carpenter D, Peterson EC, Gentry WB, West M, Che Y, Carroll FI, Owens SM.

Vaccine. 2009 Nov 23;27(50):7011-20. doi: 10.1016/j.vaccine.2009.09.072. Epub 2009 Oct 1.

16.

Open-label pilot study of modafinil for methamphetamine dependence.

McGaugh J, Mancino MJ, Feldman Z, Chopra MP, Gentry WB, Cargile C, Oliveto A.

J Clin Psychopharmacol. 2009 Oct;29(5):488-91. doi: 10.1097/JCP.0b013e3181b591e0.

17.

Vulnerability to (+)-methamphetamine effects and the relationship to drug disposition in pregnant rats during chronic infusion.

White SJ, Laurenzana EM, Gentry WB, Hendrickson HP, Williams DK, Ward KW, Owens SM.

Toxicol Sci. 2009 Sep;111(1):27-36. doi: 10.1093/toxsci/kfp127. Epub 2009 Jun 10.

18.

Development of active and passive human vaccines to treat methamphetamine addiction.

Gentry WB, Rüedi-Bettschen D, Owens SM.

Hum Vaccin. 2009 Apr;5(4):206-13. Epub 2009 Apr 20. Review.

19.

Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo.

Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK, Gentry WB, Tong Y.

Clin Pharmacol Ther. 2008 Jan;83(1):61-9. Epub 2007 May 9.

PMID:
17495878
20.

Intrathecal therapy-associated masses.

Meta G, Ghaleb A, Gentry WB, Firnhaber J.

Anesth Analg. 2006 Jul;103(1):260-1. No abstract available.

PMID:
16790677
21.

Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats.

Gentry WB, Laurenzana EM, Williams DK, West JR, Berg RJ, Terlea T, Owens SM.

Int Immunopharmacol. 2006 Jun;6(6):968-77. Epub 2006 Feb 9.

PMID:
16644483
22.

Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted.

Pitas G, Laurenzana EM, Williams DK, Owens SM, Gentry WB.

Drug Metab Dispos. 2006 Jun;34(6):906-12. Epub 2006 Feb 28.

PMID:
16507651
23.

Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin.

Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB, Breen P, Carrier DJ, Cheboyina S.

J Clin Pharmacol. 2006 Feb;46(2):201-13.

24.

Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats.

Byrnes-Blake KA, Laurenzana EM, Landes RD, Gentry WB, Owens SM.

Eur J Pharmacol. 2005 Oct 3;521(1-3):86-94. Epub 2005 Sep 21.

PMID:
16182279
25.
26.

Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in rats.

Milesi-Hallé A, Hendrickson HP, Laurenzana EM, Gentry WB, Owens SM.

Toxicol Appl Pharmacol. 2005 Dec 15;209(3):203-13.

PMID:
15916788
27.

In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes.

Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A.

Clin Pharmacol Ther. 2005 May;77(5):415-26.

28.

(+)-Methamphetamine-induced spontaneous behavior in rats depends on route of (+)METH administration.

Gentry WB, Ghafoor AU, Wessinger WD, Laurenzana EM, Hendrickson HP, Owens SM.

Pharmacol Biochem Behav. 2004 Dec;79(4):751-60.

PMID:
15582684
29.

In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto.

Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A.

Clin Pharmacol Ther. 2004 Nov;76(5):428-40. Erratum in: Clin Pharmacol Ther. 2005 May;77(5):456.

PMID:
15536458
30.

Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats.

Laurenzana EM, Byrnes-Blake KA, Milesi-Hallé A, Gentry WB, Williams DK, Owens SM.

Drug Metab Dispos. 2003 Nov;31(11):1320-6.

PMID:
14570763
31.

Treatment of adverse effects of excessive phencyclidine exposure in rats with a minimal dose of monoclonal antibody.

Laurenzana EM, Gunnell MG, Gentry WB, Owens SM.

J Pharmacol Exp Ther. 2003 Sep;306(3):1092-8. Epub 2003 Jun 26.

PMID:
12829731
32.

Transpleural subclavian central venous catheter placement in a child with scoliosis discovered during a thoracotomy.

Ghafoor AU, Mayhew JF, Gentry WB, Schmitz ML.

J Clin Anesth. 2003 Mar;15(2):142-4.

PMID:
12719056
33.

Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats.

Byrnes-Blake KA, Laurenzana EM, Carroll FI, Abraham P, Gentry WB, Landes RD, Owens SM.

Eur J Pharmacol. 2003 Feb 14;461(2-3):119-28.

PMID:
12586207
34.

Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans.

Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY.

Clin Pharmacol Ther. 2002 Sep;72(3):276-87.

PMID:
12235448
35.

Intravenous (+)-methamphetamine causes complex dose-dependent physiologic changes in awake rats.

Arora H, Owens SM, Gentry WB.

Eur J Pharmacol. 2001 Aug 24;426(1-2):81-7.

PMID:
11525775
36.
37.
39.

Modifications of blood volume alter the disposition of markers of blood volume, extracellular fluid, and total body water.

Krejcie TC, Henthorn TK, Gentry WB, Niemann CU, Enders-Klein C, Shanks CA, Avram MJ.

J Pharmacol Exp Ther. 1999 Dec;291(3):1308-16.

PMID:
10565856
40.

Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat.

Rivière GJ, Byrnes KA, Gentry WB, Owens SM.

J Pharmacol Exp Ther. 1999 Dec;291(3):1220-6.

PMID:
10565845
41.

Efficacy of promethazine suppositories dispensed to outpatient surgical patients.

Wright CD, Jilka J, Gentry WB.

Yale J Biol Med. 1998 Sep-Oct;71(5):391-5.

43.

The effect of halothane on the recirculatory pharmacokinetics of physiologic markers.

Avram MJ, Krejcie TC, Niemann CU, Klein C, Gentry WB, Shanks CA, Henthorn TK.

Anesthesiology. 1997 Dec;87(6):1381-93.

PMID:
9416724
44.

A recirculatory model of the pulmonary uptake and pharmacokinetics of lidocaine based on analysis of arterial and mixed venous data from dogs.

Krejcie TC, Avram MJ, Gentry WB, Niemann CU, Janowski MP, Henthorn TK.

J Pharmacokinet Biopharm. 1997 Apr;25(2):169-90.

PMID:
9408858
45.

Recirculatory pharmacokinetic models of markers of blood, extracellular fluid and total body water administered concomitantly.

Krejcie TC, Henthorn TK, Niemann CU, Klein C, Gupta DK, Gentry WB, Shanks CA, Avram MJ.

J Pharmacol Exp Ther. 1996 Sep;278(3):1050-7.

PMID:
8819485
46.

Induction and maintenance of anesthesia in dogs by intravenous administration of methohexital.

Gentry WB, Krejcie TC, Henthorn TK, Avram MJ.

Am J Vet Res. 1996 Jul;57(7):1044-9.

PMID:
8807019
47.

Effect of infusion rate on thiopental dose-response relationships. Assessment of a pharmacokinetic-pharmacodynamic model.

Gentry WB, Krejcie TC, Henthorn TK, Shanks CA, Howard KA, Gupta DK, Avram MJ.

Anesthesiology. 1994 Aug;81(2):316-24; discussion 25A.

PMID:
8053580
48.

Reevaluation of a maneuver to visualize the anterior larynx after intubation.

Gentry WB, Shanks CA.

Anesth Analg. 1993 Jul;77(1):161-3.

PMID:
8317725
49.

A pharmacokinetic-pharmacodynamic model for quantal responses with thiopental.

Shanks CA, Avram MJ, Krejcie TC, Henthorn TK, Gentry WB.

J Pharmacokinet Biopharm. 1993 Jun;21(3):309-21.

PMID:
8258770

Supplemental Content

Loading ...
Support Center